Striverdi Respimat
(Olodaterol)ApprovedSmall molecule
Boehringer IngelheimStriverdi Respimat is a small molecule that works as a Beta-2 Adrenergic Receptor Agonist.[2] It is being used across 5 indications, with its most advanced program in Approved.[1]
Striverdi Respimat is one of 153 small molecule programs targeting Asthma. It is currently in Approved.
5
Indications
35
Total Trials
0
Active Trials
152
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
175 competitors in Asthma
#DrugCompanyPhaseTrials
1Striverdi Respimat
Boehringer IngelheimApproved
Celexa
AbbViePreclinical
Arcoxia
NovartisPreclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
DUPIXENT
RegeneronPreclinical
Paracetamol
GSKPreclinical
Blood Withdrawn
Emergent BioSolutionsPreclinical
Aclidinium Bromide
AstraZenecaPreclinical
Blood Collection
AAssistance Publique - Hôpitaux de Paris
Preclinical
Lexapro
SShirley Ryan AbilityLab
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Obstructive Pulmonary Disease12 trials
Show 9 more trials
COPD5 trials
Asthma5 trials
Treatment2 trials
7 more indications
Corticosteroids1 trial
Salmeterol1 trial
Physical Activity1 trial
Function1 trial
Regulatory
FDA Approval Timeline[4]
Jul 31, 2014
STRIVERDI RESPIMAT
NDA NDA203108
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Olodaterol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Beta-2 Adrenergic Receptor Agonist[2]
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company